<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008617</url>
  </required_header>
  <id_info>
    <org_study_id>STU00085894</org_study_id>
    <secondary_id>STU00085894</secondary_id>
    <nct_id>NCT02008617</nct_id>
  </id_info>
  <brief_title>Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction</brief_title>
  <official_title>Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Outpatients scheduled to have ACL surgery typically receive a femoral nerve block to provide
      analgesia for the front of the knee. Postoperatively, these patients will often report pain
      in the back of the knee. Local anesthetic infiltration of the posterior aspect of the knee
      results in blockade of the genicular nerves of the posterior knee. These nerves originate off
      of the tibial and common peroneal nerves and their blockade will result in improved posterior
      knee pain relief and may decrease narcotic consumption compared to patients who receive the
      same infiltration with normal saline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Femoral nerve blocks are commonly used to provide postoperative analgesia for ACL surgery.
      The limitation of these blocks is the incomplete analgesia they provide of the knee joint
      subjecting the patient to posterior knee pain. As a result, some of these patients receive
      rescue sciatic blocks in the postoperative care unit to cover posterior knee pain. The
      sciatic block provides excellent analgesia for the posterior knee; however its blockade
      invariably affects other territories of the sciatic nerve such as the lower leg and foot. For
      ACL surgery, the loss of sensation and/or motor strength to this area is unnecessary and may
      make ambulation more difficult. The ability to ambulate with minimal assistance may be more
      important for a patient undergoing an outpatient surgery when compared to an inpatient
      surgery.

      At the posterior knee, the sciatic nerve branches off into the tibial and common peroneal
      nerves which give rise to sensory fibers that innervate the posterior knee. We propose
      targeting these terminal fibers in the popliteal fossa by infiltrating local anesthetic
      between the distal femoral shaft and popliteal artery thereby providing posterior knee
      analgesia without affecting the lower leg.This application of this block has not been studied
      in patients having ACL surgery. A single interim analysis is scheduled after the data for 50
      cases are available.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to lack of subject recruitment
  </why_stopped>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Opioid consumption (mg morphine equivalents)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Pain Burden at 24hrs</time_frame>
    <description>Numeric Rating Scale (NRS) (NRS pain scores; 0 = no pain,10 = excruciating pain) in the back of the knee recorded every 4 hours up to 24hrs following surgery. Pain Bruden scale ranges from 0 (no pain) to 240 (extreme pain). For example, pain burden of 120 is equivalent to a NRS score of 5 out of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>24hr</time_frame>
    <description>Patient satisfaction with pain control scale ranges from 0 (no satisfaction) to 10 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery (QoR15)</measure>
    <time_frame>24hrs</time_frame>
    <description>Quality of recovery (QoR15) is a questionnaire that asks 15 questions regarding how the participant has felt in the last 24 hours. Each question is followed by an 11-point numerical rating scale (0 = &quot;none of the time&quot; to 10 = &quot;all of the time&quot;; maximum score 150). The higher the QoR15 total score, the worse the quality of recovery reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rupture of Anterior Cruciate Ligament</condition>
  <arm_group>
    <arm_group_label>Study Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative free normal saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
    <arm_group_label>Study Drug</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free normal saline</intervention_name>
    <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
    <arm_group_label>Preservative free normal saline</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients who are presenting for ACL reconstruction

          2. candidates for peripheral nerve blocks patients

          3. ASA 1-3

        Exclusion Criteria:

          1. Patient refusal

          2. ASA Classification of 4 or higher

          3. Pre-existing neuropathy in the femoral or sciatic distribution

          4. Coagulopathy

          5. Infection at the site

          6. Non-English speaking or non-reading patients

          7. Chronic opioid use (&gt;3months)

          8. Pregnancy

          9. Any other contra-indication to regional anesthesia

         10. Failed femoral nerve block

         11. Sciatic nerve block placed due to severe pain not managed by intravenous and oral
             agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohit Rahangdale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <results_first_submitted>March 8, 2017</results_first_submitted>
  <results_first_submitted_qc>March 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Rohit Rahangdale</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Anterior cruciate ligament reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Drug</title>
          <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
        </group>
        <group group_id="P2">
          <title>Preservative Free Normal Saline</title>
          <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug</title>
          <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
        </group>
        <group group_id="B2">
          <title>Preservative Free Normal Saline</title>
          <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="B2" value="29" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="B3" value="27" lower_limit="23" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opioid Consumption</title>
        <description>Opioid consumption (mg morphine equivalents)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
          </group>
          <group group_id="O2">
            <title>Preservative Free Normal Saline</title>
            <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Opioid consumption (mg morphine equivalents)</description>
          <units>mg morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="40" upper_limit="70"/>
                    <measurement group_id="O2" value="70" lower_limit="50" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score</title>
        <description>Numeric Rating Scale (NRS) (NRS pain scores; 0 = no pain,10 = excruciating pain) in the back of the knee recorded every 4 hours up to 24hrs following surgery. Pain Bruden scale ranges from 0 (no pain) to 240 (extreme pain). For example, pain burden of 120 is equivalent to a NRS score of 5 out of 10.</description>
        <time_frame>Pain Burden at 24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
          </group>
          <group group_id="O2">
            <title>Preservative Free Normal Saline</title>
            <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score</title>
          <description>Numeric Rating Scale (NRS) (NRS pain scores; 0 = no pain,10 = excruciating pain) in the back of the knee recorded every 4 hours up to 24hrs following surgery. Pain Bruden scale ranges from 0 (no pain) to 240 (extreme pain). For example, pain burden of 120 is equivalent to a NRS score of 5 out of 10.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Score at Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="58" upper_limit="160"/>
                    <measurement group_id="O2" value="135" lower_limit="112" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Score during plantar flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="50" upper_limit="182"/>
                    <measurement group_id="O2" value="128" lower_limit="96" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Rest</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Plantar Flexion</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient satisfaction with pain control scale ranges from 0 (no satisfaction) to 10 (very satisfied).</description>
        <time_frame>24hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
          </group>
          <group group_id="O2">
            <title>Preservative Free Normal Saline</title>
            <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient satisfaction with pain control scale ranges from 0 (no satisfaction) to 10 (very satisfied).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Recovery (QoR15)</title>
        <description>Quality of recovery (QoR15) is a questionnaire that asks 15 questions regarding how the participant has felt in the last 24 hours. Each question is followed by an 11-point numerical rating scale (0 = “none of the time” to 10 = “all of the time”; maximum score 150). The higher the QoR15 total score, the worse the quality of recovery reported.</description>
        <time_frame>24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
          </group>
          <group group_id="O2">
            <title>Preservative Free Normal Saline</title>
            <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery (QoR15)</title>
          <description>Quality of recovery (QoR15) is a questionnaire that asks 15 questions regarding how the participant has felt in the last 24 hours. Each question is followed by an 11-point numerical rating scale (0 = “none of the time” to 10 = “all of the time”; maximum score 150). The higher the QoR15 total score, the worse the quality of recovery reported.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="84" upper_limit="110"/>
                    <measurement group_id="O2" value="102" lower_limit="80" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24hr following surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Drug</title>
          <description>Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000</description>
        </group>
        <group group_id="E2">
          <title>Preservative Free Normal Saline</title>
          <description>Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rohit Rahangdale, M.D.</name_or_title>
      <organization>Northwestern University, Feinberg School of Medicine</organization>
      <phone>312-695-4814</phone>
      <email>rrahangd@nmff.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

